Full-Time

Associate Director

Regulatory Affairs Medical Writing

Beeline Medicines

Beeline Medicines

51-200 employees

Clinical-stage biotech developing precision autoimmune therapies

Compensation Overview

$193k - $215k/yr

+ Bonus + Equity

Remote in USA

Remote

Periodic visits to Beeline offices may be required.

Master's, PharmD, PhD

Category
Content & Writing
Legal & Compliance

Get referred to Beeline Medicines

See people who can refer or advise you

Requirements
  • Education: Advanced degree (PhD, PharmD, or master's level) in life sciences, pharmacology, biomedical sciences, or a related discipline required.
  • Minimum of 7+ years of medical writing experience in the pharmaceutical or biotech industry.
  • Extensive experience authoring and overseeing regulatory submissions in ICH CTD format, including CSRs, ISS/ISE, IBs, and IND/CTA packages.
  • Demonstrated ability to manage multiple concurrent document deliverables and writing teams in a high-priority regulatory environment.
  • Thorough knowledge of FDA and EMA regulatory writing requirements, ICH E3, E6, E8, and M4 guidelines, and applicable pharmacovigilance documentation standards.
  • Experience developing and enforcing Medical Writing SOPs, style guides, and document templates in a regulated pharmaceutical environment.
  • Proficiency with document management systems, electronic submission tools, and publishing platforms such as Veeva Vault or equivalent.
  • Strong publication planning experience, including familiarity with ICMJE authorship guidelines, journal submission processes, and scientific congress submission requirements.
  • Exceptional written and verbal communication skills with demonstrated ability to translate complex scientific, regulatory, or operational content for diverse audiences, including executive leadership, clinical teams, and external partners.
  • Skilled at preparing and delivering compelling presentations, briefing documents, and strategic updates to cross-functional leadership teams and board-level stakeholders.
  • Strong active listening skills and the ability to synthesize input from diverse perspectives into clear, actionable communications that build alignment and drive decision-making.
  • Strong track record of contributing to regulatory submissions and cross-functional approval processes.
Responsibilities
  • Own day‑to‑day execution of medical writing activities, contributing directly to authoring and quality review while coordinating internal and external resources to ensure high‑quality, on‑time delivery of regulatory and scientific documents.
  • Author, coordinate, and review key clinical and regulatory documents, including protocols and amendments, CSRs, IBs, SAPs, ICFs, INDs/CTAs, and selected BLA/NDA components, ensuring scientific accuracy, regulatory compliance, and consistency of content.
  • Contribute to shaping the strategy for submission narratives and key messages, leading scientific messaging consistency across CTD modules. Represent Medical Writing in relevant cross‑functional and governance forums to support alignment on submission strategy and document readiness.
  • Collaborate closely with Clinical Development, Nonclinical, Biostatistics, Safety, and Regulatory Affairs to plan, sequence, and execute document deliverables, coordinating cross‑functional review cycles and ensuring timely, integrated input.
  • Provide practical guidance and oversight to internal contributors and external medical writers, including vendor management, scope definition, deliverable tracking, and consistent application of Medical Writing standards, templates, and SOPs aligned with ICH and regional requirements.
  • Own document timelines and individually or in collaboration with project management, maintain and actively manage integrated trackers across programs, partnering with line management to align on resourcing needs, anticipate and mitigate bottlenecks, and finding creative ways to provide regular, transparent status updates to cross‑functional teams and leadership.
  • Establish a clear process for the authoring, review, QC and approval of regulatory documents to be submitted to heath authorities. Develop training materials for the cross functional team to ensure adoption of the agreed process.
  • Collaborate with IT, Quality, and Regulatory stakeholders to evaluate AI and digital tools that enhance medical writing efficiency and consistency, while ensuring compliance with data privacy, system validation, and regulatory expectations; remain current on evolving regulatory guidance and industry best practices.
  • Perform other duties and responsibilities as assigned.
Desired Qualifications
  • Deep scientific expertise in immunology, inflammation, or autoimmune disease is strongly preferred, with the ability to rapidly acquire technical knowledge in new therapeutic areas.
  • Experience building or scaling a Medical Writing function in an early-stage or rapidly growing biotech organization is highly desirable.

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million total.
  • Existing investors Bain Capital, CPP Investments, and BMS doubled down before Phase 2 data.
  • Management says pivotal lupus preparation has started, signaling confidence in a registrational path.

What critics are saying

  • Afimetoran's Phase 2 lupus readout in 2H 2026 is the company's defining binary event.
  • Merck KGaA's enpatoran missed the SLE endpoint in 2025, weakening the TLR7/8 thesis.
  • If afimetoran disappoints, Beeline's five-asset platform becomes a costly BMS asset recycle.

What makes Beeline Medicines unique

  • Beeline launched in April 2026 with five BMS-licensed programs, not discovery-stage science.
  • Afimetoran is a once-daily oral TLR7/8 inhibitor, designed for mechanistically precise lupus suppression.
  • Saqib Islam built SpringWorks into a $3.9 billion Merck KGaA acquisition in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Health Insurance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-12%

1 year growth

-12%

2 year growth

-12%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...